Abstracts tagged "Heterogeneous"

Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Mimi Kim¹, Kith Pradhan ¹, Peter Izmirly ², Kenneth Kalunian ³, Leslie Hanrahan ⁴ and Joan Merrill ⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²New York University School of Medicine, New York, ³University of California at San Diego, San Diego, ⁴Lupus Foundation of America, Washington DC, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…
Abstract Number: 916 • 2018 ACR/ARHP Annual Meeting
Integrative Analysis of Multi-Omics Data in an Ethnically Diverse Lupus Cohort Identifies Distinct Molecular Subtypes of SLE
Cristina Lanata¹, Ishan Paranjpe², Joanne Nitiham³, Kimberly Taylor⁴, Brooke Rhead⁵, Milena Gianfrancesco⁶, Lisa Barcellos⁷, Louise Murphy⁸, Patricia Katz⁹, Laura Trupin⁶, Jinoos Yazdany², Maria Dall'Era², Marina Sirota¹⁰ and Lindsey A. Criswell⁹, ¹Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵University of California, Berkeley, Berkeley, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷School of Public Health, UC Berkeley, Berkeley, CA, ⁸Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease with heterogeneous disease manifestations and outcomes. We aimed to define how molecular differences underlie this…
Abstract Number: 2999 • 2018 ACR/ARHP Annual Meeting
Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?
Aniket Kawatkar¹, J An², TC Cheetham², Kiran Gupta³, Alexander Marshall⁴, Eric Haupt¹, Gary Okano³ and Tammy Curtice⁵, ¹Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Western University of Health Sciences, Pomona, CA, ³HEOR, Bristol-Myers Squibb, Princeton, NJ, ⁴HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Rheumatoid Arthritis (RA) patients who are anti-citrullinated peptide antibody (ACPA) positive are prone to more severe structural damage, radiographic progression and inferior response to…
Abstract Number: 756 • 2017 ACR/ARHP Annual Meeting
Novel Machine Learning Classifier Accurately Predicts Intrinsic Molecular Subsets for Patients with Systemic Sclerosis
Jennifer Franks¹, Viktor Martyanov¹, Guoshuai Cai¹ and Michael L. Whitfield², ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: High-throughput gene expression profiling of skin biopsies from patients with systemic sclerosis (SSc) has identified four “intrinsic” gene expression subsets conserved across multiple cohorts…
Abstract Number: 383 • 2016 ACR/ARHP Annual Meeting
Potential Biomarkers of Disease Activity in Juvenile Idiopathic Arthritis – Data from the Portuguese Register, Reuma.Pt
Ana Filipa Mourão^1,2,3, MJ Santos⁴, Mónica Eusébio⁵, Ana Lopes⁶, Filipa Ramos⁷, Manuel Salgado⁸, Paula Estanqueiro⁹, Jose Antonio Melo Gomes¹⁰, Fernando Magalhaes Martins¹¹, José Antonio Costa¹², Ana Carolina Furtado¹³, Ricardo Figueira¹⁴, Iva Brito^15,16,17, Jaime Branco^18,19, João E. Fonseca²⁰ and Helena Canhão²¹, ¹NOVA Medical School - Faculdade Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal, ²Centro Hospitalar Lisboa Ocidental (CHLO- E.P.E.), Lisbon, Portugal, ³Rheumatology, Instituto de Medicina Molecular, Lisbon, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Sociedade Portuguesa de Reumatologia, LIsboa, Portugal, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Rheumatology and Metabolic Bone Diseases Department, Santa Maria Hospital,CHLN, Lisbon, Portugal, ⁸Pediatrics, Centro Hospitalar de Coimbra, Coimbra, Portugal, ⁹Pediatrics, Centro Hospitalar da Universidade de Coimbra, Coimbra, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Portuguese Society of Rheumatology, Lisbon, Portugal, ¹²Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹³Rheumatology, Hospital do Divino Espírito Santo, Ponta Delgada, São Miguel, Portugal, ¹⁴Rheumatology, Hospital Dr. Nélio Mendonça, Funchal, Portugal, ¹⁵Rheumatology, Centro Hospitalar do Pirto, Hospital de São João, Porto, Portugal, ¹⁶Rua Raul Caldevilla 126-2 Dto, Hospital Sao Joao, Porto, Portugal, ¹⁷Faculdade de Medicina da Universidade do Porto, Porto, Portugal, ¹⁸Rheumatology, CHLO, Hospital Egas Moniz, Lisbon, Portugal, ¹⁹CEDOC, Nova Medical School, Lisbon, Portugal, ²⁰Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, Lisboa, Portugal, ²¹Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
, IL6, IL10, IL17 and TNF in patients with JIA, and detect their relation to disease activity. Results: 281 patients, 66% female, mean age 17.3±10…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].